Adeona, Intrexon Collaborate For Synthetic DNA Therapy for Pulmonary Arterial HypertensionThe Ann Arbor pharmaceutical firm Adeona Pharmaceuticals Inc. and the Human Therapeutics Division of Intrexon Corp., Monday announced the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension.
Adeona Loss Grows, But Drug Trials ContinueThe pharma startup Adeona Pharmaceuticals Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, reported its third quarter 2011 financial results Monday.
HR Notices From November 2The latest personnel, leadership and boardroom news from Michigan's technology-focused companies and institutions
Adeona Completes Enrollment In Phase II Trial Of MS DrugAdeona Pharmaceuticals Inc. said Monday that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta oral estriol drug candidate for relapsing-remitting multiple sclerosis in women.
Adeona Loss Grows, But Other Markers HappierThe Ann Arbor pharma startup Adeona Pharmaceuticals Inc. (Amex: AEN) this week reported a larger loss but also larger sales and more positive developments for the first quarter ended March 31.
Adeona to Raise $4 Million in Registered Direct OfferingThe Ann Arbor pharma startup Adeona Pharmaceuticals Inc. (Amex: AEN) said Friday that it had executed an agreement for the sale of approximately 2.85 million shares of its common stock at $1.40 per share to two new institutional investors in a registered direct offering for $4 million in gross proceeds
Event Notices From January 18The latest event and meeting notices from Michigan's technology community, before they're posted on the GLITR IT Calendar
Event Notices From January 6